Clinical Trial Update: Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments

View source ↗

Summary

AstraZeneca reports the completion of a trial evaluating cardiovascular event risk in patients with Type 2 diabetes initiating oral antidiabetic therapies, summ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED